786616-54-4

Basic information

• Product Name: Benzoic acid, 3-amino-5-fluoro- (9CI)
• Synonyms: Benzoic acid, 3-amino-5-fluoro- (9CI);Benzoic acid,3-aMino-5-fluoro-
• CAS NO: 786616-54-4
• Molecular Formula: C7H6FNO2
• Molecular Weight: 155.1264432
• Product Categories: METHYL;HALIDE;Fluorine series
• Mol File: 786616-54-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 355.554 °C at 760 mmHg
• Flash Point: 168.833 °C
• Appearance: /Solid
• Density: 1.43 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.606
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: Benzoic acid, 3-amino-5-fluoro- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 3-amino-5-fluoro- (9CI)(786616-54-4)
• EPA Substance Registry System: Benzoic acid, 3-amino-5-fluoro- (9CI)(786616-54-4)

Safety Data

• Hazardous Substances Data: 786616-54-4(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 3-amino-5-fluoro- (9CI) is a chemical compound with the molecular formula C7H6FNO2. It is a derivative of benzoic acid and contains an amino group and a fluorine atom attached to the benzene ring. Benzoic acid, 3-amino-5-fluoro- (9CI) is commonly used in the synthesis of pharmaceuticals and agrochemicals, as well as in the production of dyes. Its properties and structure make it a valuable building block for the creation of various organic compounds, and its versatility has led to its widespread use in the chemical industry. Additionally, it has been found to have potential biological activity, making it an area of interest for further research and development.

InChI:InChI=1/C7H6FNO2/c8-5-1-4(7(10)11)2-6(9)3-5/h1-3H,9H2,(H,10,11)

Upstream product

• 14027-75-9 3-nitro-5-fluorobenzoic acid 

Downstream Products

• 1448806-67-4 N-(3-fluoro-5-(oxazolo[4,5-b]pyridin-2-yl)phenyl)furan-2-carboxamide 

Relevant articles and documents

Berotralstat (BCX7353): Structure-Guided Design of a Potent, Selective, and Oral Plasma Kallikrein Inhibitor to Prevent Attacks of Hereditary Angioedema (HAE)

Hereditary angioedema (HAE) is a rare and potentially life-threatening disease that affects an estimated 1 in 50000 individuals worldwide. Until recently, prophylactic HAE treatment options were limited to injectables, a burdensome administration route that has driven the need for an oral treatment. A substantial body of evidence has shown that potent and selective plasma kallikrein inhibitors that block the generation of bradykinin represent a promising approach for the treatment of HAE. Berotralstat (BCX7353, discovered by BioCryst Pharmaceuticals using a structure-guided drug design strategy) is a synthetic plasma kallikrein inhibitor that is potent and highly selective over other structurally related serine proteases. This once-daily, small-molecule drug is the first orally bioavailable prophylactic treatment for HAE attacks, having successfully completed a Phase III clinical trial (meeting its primary end point) and recently receiving the U.S. Food and Drug Administration's approval for the prophylactic treatment of HAE attacks in patients 12 years and older.